^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NKG2D-based dual CAR T
i
Other names: NKG2D-based dual CAR T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Celyad Oncology
Drug class:
NKG2D-targeted CAR-T immunotherapy
Related drugs:
